Arbutus Biopharma Corporation
ABUS
$3.14
$0.020.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -65.98% | -69.69% | -57.25% | -60.80% | -53.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -65.98% | -69.69% | -57.25% | -60.80% | -53.51% |
| Cost of Revenue | -26.68% | -20.60% | -13.02% | -15.90% | -12.69% |
| Gross Profit | 13.85% | 1.40% | -5.75% | -13.20% | -22.41% |
| SG&A Expenses | 14.92% | 4.04% | 23.49% | 20.23% | 26.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.96% | -15.31% | -5.86% | -9.40% | -5.93% |
| Operating Income | 5.56% | -0.10% | -10.33% | -15.07% | -23.43% |
| Income Before Tax | 4.02% | -1.63% | -5.70% | -6.22% | -12.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.02% | -1.63% | -5.70% | -6.22% | -4.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.02% | -1.63% | -5.70% | -6.22% | -4.89% |
| EBIT | 5.56% | -0.10% | -10.33% | -15.07% | -23.43% |
| EBITDA | 5.63% | -0.03% | -10.36% | -15.29% | -24.00% |
| EPS Basic | 13.93% | 8.39% | 4.25% | 3.20% | 4.42% |
| Normalized Basic EPS | 17.02% | 11.81% | 3.22% | -0.15% | -5.71% |
| EPS Diluted | 13.40% | 8.17% | 4.03% | 2.97% | 4.21% |
| Normalized Diluted EPS | 17.02% | 11.81% | 3.22% | -0.15% | -5.71% |
| Average Basic Shares Outstanding | 11.83% | 10.82% | 10.32% | 9.85% | 9.94% |
| Average Diluted Shares Outstanding | 11.83% | 10.82% | 10.32% | 9.85% | 9.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
